Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.

BOOSTRIX provided uncompromised immunogenicity against tetanus and diphtheria with added pertussis protection in adolescents and adults1

In separate clinical studies in adolescents 10-18 years of age, and adults 19-64 years of age, pertussis antibody concentrations (GMCs) following BOOSTRIX were noninferior to those observed in infants who received a 3-dose primary vaccination series with INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). 3,4

Serologic correlates of protection for pertussis have not been established. Licensure of BOOSTRIX was based on immune response to the vaccine and bridging to clinical efficacy data.1

In adolescents 10-18 years of age, antibody responses to tetanus and diphtheria toxoids 1 month following BOOSTRIX were compared with Td vaccine1

N = Number of Vaccinees.
CI = Confidence interval.
Tdap = Tetanus and diphtheria.

In adults 19-64 years of age, antibody responses to tetanus and diphtheria toxoids 1 month following BOOSTRIX were compared with Tdap vaccine1

N = Number of Vaccinees.
CI = Confidence interval.
Tdap = Tetanus, diphtheria, and acellular pertussis.

In adolescents and adults, anti-tetanus and anti-diphtheria seroprotective rates (≥0.1 IU/mL) for BOOSTRIX were comparable to the control Td/Tdap vaccine 1 month after a single dose.3,4

Help protect patients 65 years of age and older with BOOSTRIX

BOOSTRIX is the only Tdap vaccine that has demonstrated uncompromised immunogenicity against Td with added pertussis protection in individuals 65 years of age and older.1

In a clinical study in adults 65 years of age and older, pertussis antibody concentrations (GMCs) following BOOSTRIX were noninferior to those observed in infants who received a 3-dose primary vaccination series with INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).1

Serologic correlates of protection for pertussis have not been established. Licensure of BOOSTRIX was based on immune response to the vaccine and bridging to clinical efficacy data.1

In adults ≥65 years of age, antibody responses to tetanus and diphtheria toxoids 1 month following BOOSTRIX were comparable to Td vaccine1

N = Number of Vaccinees.
CI = Confidence interval.
Td = Tetanus and diphtheria.

Anti-tetanus and anti-diphtheria seroprotective rates (percentages of subjects with antibody levels ≥0.1 UI/mL) for BOOSTRIX were comparable to the control Td vaccine 1 month after a single dose.1

References:

  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-1093.
  4. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27(5):765-772.
  5. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.